Andrew Leonard Laccetti

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Chung‐Han Lee, Martin H. Voss, Maria I. Carlo et al. · Journal of Clinical Oncology · 2022 · 195 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

Kelly N. Fitzgerald, Chung‐Han Lee, Martin H. Voss et al. · European Urology · 2024 · 33 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

Chung‐Han Lee, Martin H. Voss, Maria I. Carlo et al. · Journal of Clinical Oncology · 2021 · 32 citations

Medicine, Oncology, Pharmacotherapy +17

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

Andrew Leonard Laccetti, Benjamin Garmezy, Lianchun Xiao et al. · Cancer Medicine · 2021 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).

Andrew Leonard Laccetti, Gurkamal Chatta, Nicholas Iannotti et al. · Journal of Clinical Oncology · 2023 · 18 citations

Medicine, Oncology, Pharmacology +17